Monday, May 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Medical Countermeasures for Acute Radiation Syndrome

by Global Biodefense Staff
August 17, 2012

The National Institute of Allergy and Infectious Diseases (NIAID) has issued a Broad Agency Announcement (BAA) soliciting proposals for development of products for treatment of radiation exposures resulting from nuclear and radiological attacks.

The BAA seeks organizations with the capabilities to advance the development of candidate medical countermeasures (MCMs) for gastrointestinal acute radiation syndrome (GI-ARS). For this funding activity, it is anticipated that candidate MCMs will enter the evaluation and development pathway at various stages, from early research to post marketing (for drugs or biologics that are already licensed or approved for other indications). Offerors are expected to provide a Statement of Work based on the stage of the candidate and the work that needs to be performed to advance the MCM.

NIAID’s overall goal is development of products for treatment of radiation exposures resulting from nuclear and radiological attacks to the stage where products are eligible for advanced product development by the Biomedical Advanced Research and Development Authority or acquisition under the Project BioShield Act of 2004.

It is anticipated that 2-4 contracts will be awarded for a 3-year period of performance beginning on or about July 15, 2013. NIAID estimates that the average annual total cost will be $1-2 million per contract award per year depending on the length and scope of the project. Further details are available under Solicitation Number: BAA-NIAID-DAIT-NIHAI2012147. The current proposal deadline is November 15, 2012.

Update: The response deadline has been extended to November 29, 2012 due to Superstorm Sandy.

Tags: BAARadiation

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC